Amy C Degnim1, William D Dupont2, Derek C Radisky3, Robert A Vierkant4, Ryan D Frank5, Marlene H Frost6, Stacey J Winham4, Melinda E Sanders7, Jeffrey R Smith8, David L Page9, Tanya L Hoskin4, Celine M Vachon10, Karthik Ghosh11, Tina J Hieken12, Lori A Denison13, Jodi M Carter14, Lynn C Hartmann6, Daniel W Visscher14. 1. Division of Subspecialty General Surgery, Mayo Clinic, Rochester, Minnesota. degnim.amy@mayo.edu. 2. Department of Biostatistics, Vanderbilt University, Nashville, Tennessee. 3. Cancer Biology, Mayo Clinic, Jacksonville, Florida. 4. Division of Biomedical Statistics and Informatics, Mayo Clinic, Rochester, Minnesota. 5. Division of Biomedical Statistics and Informatics, Mayo Clinic, Jacksonville, Florida. 6. Division of Medical Oncology, Mayo Clinic, Rochester, Minnesota. 7. Department of Pathology, Microbiology, and Immunology, Vanderbilt University, Nashville, Tennessee. 8. Division of Genetic Medicine, Vanderbilt University, Nashville, Tennessee. 9. Breast Pathology Consultants, Nashville, Tennessee. 10. Division of Epidemiology, Mayo Clinic, Rochester, Minnesota. 11. Breast Diagnostic Clinic, Mayo Clinic, Rochester, Minnesota. 12. Division of Subspecialty General Surgery, Mayo Clinic, Rochester, Minnesota. 13. Information Technology, Mayo Clinic, Rochester, Minnesota. 14. Division of Anatomic Pathology, Mayo Clinic, Rochester, Minnesota.
Abstract
BACKGROUND: Women with atypical hyperplasia (AH) on breast biopsy have a substantially increased risk of breast cancer (BC). Here the BC risk for the extent and subtype of AH is reported for 2 separate cohorts. METHODS: All samples containing AH were included from 2 cohorts of women with benign breast disease (Mayo Clinic and Nashville). Histology review quantified the number of foci of atypical ductal hyperplasia (ADH) and atypical lobular hyperplasia (ALH). The BC risk was stratified for the number of AH foci within AH subtypes. RESULTS: The study included 708 Mayo AH subjects and 466 Nashville AH subjects. In the Mayo cohort, an increasing number of foci of AH was associated with a significant increase in the risk of BC both for ADH (relative risks of 2.61, 5.21, and 6.36 for 1, 2, and ≥3 foci, respectively; P for linear trend = .006) and for ALH (relative risks of 2.56, 3.50, and 6.79 for 1, 2, and ≥3 foci, respectively; P for linear trend = .001). In the Nashville cohort, the relative risks of BC for ADH were 2.70, 5.17, and 15.06 for 1, 2, and ≥3 foci, respectively (P for linear trend < .001); for ALH, the relative risks also increased but not significantly (2.61, 3.48, and 4.02, respectively; P = .148). When the Mayo and Nashville samples were combined, the risk increased significantly for 1, 2, and ≥3 foci: the relative risks were 2.65, 5.19, and 8.94, respectively, for ADH (P < .001) and 2.58, 3.49, and 4.97, respectively, for ALH (P = .001). CONCLUSIONS: In 2 independent cohort studies of benign breast disease, the extent of atypia stratified the long-term BC risk for ADH and ALH. Cancer 2016;122:2971-2978.
BACKGROUND:Women with atypical hyperplasia (AH) on breast biopsy have a substantially increased risk of breast cancer (BC). Here the BC risk for the extent and subtype of AH is reported for 2 separate cohorts. METHODS: All samples containing AH were included from 2 cohorts of women with benign breast disease (Mayo Clinic and Nashville). Histology review quantified the number of foci of atypical ductal hyperplasia (ADH) and atypical lobular hyperplasia (ALH). The BC risk was stratified for the number of AH foci within AH subtypes. RESULTS: The study included 708 MayoAH subjects and 466 Nashville AH subjects. In the Mayo cohort, an increasing number of foci of AH was associated with a significant increase in the risk of BC both for ADH (relative risks of 2.61, 5.21, and 6.36 for 1, 2, and ≥3 foci, respectively; P for linear trend = .006) and for ALH (relative risks of 2.56, 3.50, and 6.79 for 1, 2, and ≥3 foci, respectively; P for linear trend = .001). In the Nashville cohort, the relative risks of BC for ADH were 2.70, 5.17, and 15.06 for 1, 2, and ≥3 foci, respectively (P for linear trend < .001); for ALH, the relative risks also increased but not significantly (2.61, 3.48, and 4.02, respectively; P = .148). When the Mayo and Nashville samples were combined, the risk increased significantly for 1, 2, and ≥3 foci: the relative risks were 2.65, 5.19, and 8.94, respectively, for ADH (P < .001) and 2.58, 3.49, and 4.97, respectively, for ALH (P = .001). CONCLUSIONS: In 2 independent cohort studies of benign breast disease, the extent of atypia stratified the long-term BC risk for ADH and ALH. Cancer 2016;122:2971-2978.
Authors: Paul E Goss; James N Ingle; José E Alés-Martínez; Angela M Cheung; Rowan T Chlebowski; Jean Wactawski-Wende; Anne McTiernan; John Robbins; Karen C Johnson; Lisa W Martin; Eric Winquist; Gloria E Sarto; Judy E Garber; Carol J Fabian; Pascal Pujol; Elizabeth Maunsell; Patricia Farmer; Karen A Gelmon; Dongsheng Tu; Harriet Richardson Journal: N Engl J Med Date: 2011-06-04 Impact factor: 91.245
Authors: Erika A Waters; Timothy S McNeel; Worta McCaskill Stevens; Andrew N Freedman Journal: Breast Cancer Res Treat Date: 2012-05-24 Impact factor: 4.872
Authors: Melinda E Sanders; David L Page; Jean F Simpson; Peggy A Schuyler; W Dale Plummer; William D Dupont Journal: Cancer Date: 2006-04-01 Impact factor: 6.860
Authors: Bernard Fisher; Joseph P Costantino; D Lawrence Wickerham; Reena S Cecchini; Walter M Cronin; Andre Robidoux; Therese B Bevers; Maureen T Kavanah; James N Atkins; Richard G Margolese; Carolyn D Runowicz; Joan M James; Leslie G Ford; Norman Wolmark Journal: J Natl Cancer Inst Date: 2005-11-16 Impact factor: 13.506
Authors: Lynn C Hartmann; Derek C Radisky; Marlene H Frost; Richard J Santen; Robert A Vierkant; Lorelle L Benetti; Yaman Tarabishy; Karthik Ghosh; Daniel W Visscher; Amy C Degnim Journal: Cancer Prev Res (Phila) Date: 2014-01-30
Authors: David L Page; Peggy A Schuyler; William D Dupont; Roy A Jensen; W Dale Plummer; Jean F Simpson Journal: Lancet Date: 2003-01-11 Impact factor: 79.321
Authors: Laura C Collins; Sarah A Aroner; James L Connolly; Graham A Colditz; Stuart J Schnitt; Rulla M Tamimi Journal: Cancer Date: 2015-11-13 Impact factor: 6.860
Authors: S G Smith; I Sestak; A Forster; A Partridge; L Side; M S Wolf; R Horne; J Wardle; J Cuzick Journal: Ann Oncol Date: 2015-12-08 Impact factor: 32.976
Authors: Amy C Degnim; Daniel W Visscher; Derek C Radisky; Marlene H Frost; Robert A Vierkant; Ryan D Frank; Stacey J Winham; Celine M Vachon; William D Dupont; Lynn C Hartmann Journal: Cancer Date: 2016-06-28 Impact factor: 6.860
Authors: Amy C Degnim; Stacey J Winham; Ryan D Frank; V Shane Pankratz; William D Dupont; Robert A Vierkant; Marlene H Frost; Tanya L Hoskin; Celine M Vachon; Karthik Ghosh; Tina J Hieken; Jodi M Carter; Lori A Denison; Brendan Broderick; Lynn C Hartmann; Daniel W Visscher; Derek C Radisky Journal: J Clin Oncol Date: 2018-04-20 Impact factor: 44.544
Authors: Osman Toktaş; Sadi Elasan; Ümit Haluk İliklerden; Remzi Erten; Ali Rıza Karayil; Abdulselam Özdemir; Fırat Aslan; Serhat Binici; İbrahim Özalp; Enes Şentürk Journal: Eur J Breast Health Date: 2020-12-24
Authors: Mustapha Abubakar; Shaoqi Fan; Erin Aiello Bowles; Lea Widemann; Máire A Duggan; Ruth M Pfeiffer; Roni T Falk; Scott Lawrence; Kathryn Richert-Boe; Andrew G Glass; Teresa M Kimes; Jonine D Figueroa; Thomas E Rohan; Gretchen L Gierach Journal: JNCI Cancer Spectr Date: 2021-02-06
Authors: R J Santen; D C Radisky; A Degnim; M H Frost; C M Vachon; K Ghosh; F Guestini; K M McNamara; H Sasano Journal: Breast Cancer Res Treat Date: 2017-03-23 Impact factor: 4.624